SMARCA4 and prostate cancer: For instance, Xiao et al. [175] found that androgen receptor (AR) and forkhead box A1 (FOXA1)-positive prostate cancer cells are sensitive to proteolysis-targeting chimera (PROTAC) degrader against SMARCA4 and SMARCA2.